TY - JOUR T1 - 177 Lu-Dotatate therapy for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors: How often do patients discontinue treatment early and why? JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 160 LP - 160 VL - 62 IS - supplement 1 AU - Gabriela Feliciano AU - Leigh-Ann DiGregorio AU - Lauren Shanbrun AU - Richard Noto Y1 - 2021/05/01 UR - http://jnm.snmjournals.org/content/62/supplement_1/160.abstract N2 - 160Objectives: The goal of this retrospective study is to evaluate how well 177 Lu-Dotatate therapy was tolerated and to give insight into the factors that lead to patients not completing the full 4-dose course of therapy. This information can help identify the patients who are best suited to benefit from this kind of therapy. Methods: All patient information was obtained via Lifespan chart review. A total of 17 patients who received 177 Lu-Dotatate therapy at Lifespan were identified between the dates of 8/10/2018 to 8/4/2020. A list of factors was collected for every patient that included age, gender, location of the primary tumor, previous treatments, performance status, the extent of disease at baseline, lab values, and the reason for discontinuing treatment. All data was securely saved in the research database REDCap. Results: Out of the 17 patients, 12 (70%) completed the full 4 dose therapy regimen and tolerated therapy well. Five patients (30%) did not complete the full 4 doses. Of the five patients who did not complete the therapy regimen, one patient declined further treatment after developing nausea and vomiting during the first dose and the other four patients weren’t able to complete treatment because of worsening cytopenia. Three out of the four patients who couldn’t complete treatment due to cytopenia had cytopenia at baseline.When looking at all 17 patients who began treatment, 5 patients started with baseline cytopenia. Two of the 5 with baseline cytopenia were able to complete the treatment while 3 could not complete the treatment.The 3 patients who had baseline cytopenia could not complete the treatment regimen for the following reasons: Patient A had low RBC and platelet counts at baseline. After three doses of Lu-177 Dotatate,, the initial cytopenias worsened, and the patient developed neutropenia. P Patient B had low RBCs at baseline and terminated treatment after the third dose of Lu-177 Dotatate due to thrombocytopenia. Patient C had low RBCs and WBCs at baseline; after one treatment with Lu-177 Dotatate, the baseline cytopenias worsened and the patient became thrombocytopenic. Conclusions: Most patients who underwent treatment with 177-Lu Dotatate tolerated it well. However, 30% of patients at our institution were unable to complete the four planned doses. The most common reason for the early termination of treatment was worsening cytopenias, mostly in patients with baseline cytopenias. This study suggests that patients with a normal range of blood cells at thestart of their treatment will more likely complete treatment than those patients who start treatment with low blood cell counts. ER -